EnsoData announced this week that it is partnering with Aeroflow to use predictive clinical AI tools to enable more timely patient care, increase patient adherence and strengthen the foundational provider-patient connection in the area of personalized sleep apnea care.

“(Our AI model) will have a transformative impact on the growing patient population who face challenges in treating their sleep apnea, by enabling Aeroflow to better prioritize the patients in their network who struggle the most on therapy and have the greatest potential health and adherence benefit from targeted coaching and intervention,” EnsoData Chief Artificial Intelligence Officer Sam Rusk said in a statement.

According to a release, EnsoData’s PAP therapy adherence AI model, EnsoTherapy, supports and empowers Aeroflow’s sleep coaches with actionable data to provide personalized support to patients who are struggling with therapy adherence.

Aeroflow is located in North Carolina. 

Financial terms were not disclosed.